
Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer
Celcuity Inc. CELC stock surged on Monday after the company reported topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, which evaluated gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant. The trial …